Whitefort Capital Sends Letter To Arbutus Biopharma Board Of Directors; Believes Now Is The Time For Arbutus To Pursue A License And Collaboration Agreement With A Strategic Partner And Explore All Options For HBV Portfolio
Whitefort Capital Sends Letter To Arbutus Biopharma Board Of Directors; Believes Now Is The Time For Arbutus To Pursue A License And Collaboration Agreement With A Strategic Partner And Explore All Options For HBV Portfolio
Believes Now Is the Logical Time for Arbutus to Pursue a License and Collaboration Agreement With a Strategic Partner and Explore All Options for HBV Portfolio
認爲現在是arbutus biopharma與戰略合作伙伴簽訂許可和合作協議,探索HBV投資組合的所有選擇的合適時機
Urges Arbutus to Commit to No Dilutive Equity Issuances or ATM Use for Another Year
敦促arbutus biopharma承諾在另一年內不進行股權稀釋或ATm使用
Whitefort Formally Requests Meeting With the Board to Ensure Alignment of Views on Path Forward
Whitefort正式請求與董事會會面,以確保對未來道路的觀點保持一致
Whitefort Capital Management, LP (together with its affiliates, "Whitefort Capital," "us" or "we"), which is a long-term investor and the third largest shareholder of Arbutus Biopharma Corp. (NASDAQ:ABUS) ("Arbutus" or the "Company") with an ownership interest of approximately 6.8% of the Company's outstanding shares, today published a letter to the Company's Board of Directors (the "Board") outlining its views on the actions Arbutus must take in order to preserve and maximize shareholder value.
Whitefort資本管理有限合夥公司(連同其關聯公司、「Whitefort資本」、「我們」或「我們」)是arbutus biopharma corp.(納斯達克:ABUS)(「arbutus」或「公司」)的長期投資者,也是arbutus biopharma corp.的第三大股東,持有公司流通股的約6.8%,今天發佈了一封致公司董事會(「董事會」)的信函,概述arbutus必須採取的行動,以維護並最大化股東價值。
譯文內容由第三人軟體翻譯。